| First Author | Liu Q | Year | 2021 |
| Journal | Cancer Lett | Volume | 520 |
| Pages | 109-120 | PubMed ID | 34237408 |
| Mgi Jnum | J:310247 | Mgi Id | MGI:6762085 |
| Doi | 10.1016/j.canlet.2021.06.014 | Citation | Liu Q, et al. (2021) NLRP3-activated bone marrow dendritic cells play antileukemic roles via IL-1beta/Th1/IFN-gamma in acute myeloid leukemia. Cancer Lett 520:109-120 |
| abstractText | The bone marrow microenvironment of acute myeloid leukemia (AML) characterized by immunosuppressive features fosters leukemia immune escape. Elucidating the immunosuppressive mechanism and developing effective immunotherapeutic strategies are necessary. Here, we found that the Th1% and IFN-gamma level were downregulated in bone marrow of AML and NLRP3-activated BMDCs promoted CD4(+) T cell differentiation into Th1 cells via IL-1beta secretion. However, IFN-gamma-producing Th1 cells were not induced by NLRP3-activated BMDCs in the presence of the NLRP3 inflammasome inhibitor MCC950 or anti-IL-1beta antibody in vitro unless exogenous IL-1beta was replenished. This inhibitory effect on Th1 differentiation was also observed in Nlrp3(-/-) mice or anti-IL-1beta antibody-treated mice. Notably, elevated Th1 cell levels promoted apoptosis and inhibited proliferation in leukemia cells via IFN-gamma secretion in vitro and in vivo. Thus, NLRP3-activated BMDCs promote the proliferation of IFN-gamma-producing Th1 cells with antileukemic effects and may provide insight into the basis for leukemia immunotherapy in patients with AML. |
